Biology (May 2022)

Should Endometrial Cancer Treatment Be Centralized?

  • Vincenzo Dario Mandato,
  • Andrea Palicelli,
  • Federica Torricelli,
  • Valentina Mastrofilippo,
  • Chiara Leone,
  • Vittoria Dicarlo,
  • Alessandro Tafuni,
  • Giacomo Santandrea,
  • Gianluca Annunziata,
  • Matteo Generali,
  • Debora Pirillo,
  • Gino Ciarlini,
  • Lorenzo Aguzzoli

DOI
https://doi.org/10.3390/biology11050768
Journal volume & issue
Vol. 11, no. 5
p. 768

Abstract

Read online

Endometrial cancer (EC) is the most common malignancy of the female genital tract in Western and emerging countries. In 2012, new cancer cases numbered 319,605, and 76,160 cancer deaths were diagnosed worldwide. ECs are usually diagnosed after menopause; 70% of ECs are diagnosed at an early stage with a favorable prognosis and a 5-year overall survival rate of 77%. On the contrary, women with advanced or recurrent disease have extremely poor outcomes because they show a low response rate to conventional chemotherapy. EC is generally considered easy to treat, although it presents a 5-year mortality of 25%. Though the guidelines (GLs) recommend treatment in specialized centers by physicians specializing in gynecologic oncology, most women are managed by general gynecologists, resulting in differences and discrepancies in clinical management. In this paper we reviewed the literature with the aim of highlighting where the treatment of EC patients requires gynecologic oncologists, as suggested by the GLs. Moreover, we sought to identify the causes of the lack of GL adherence, suggesting useful changes to ensure adequate treatment for all EC patients.

Keywords